Cargando…

HIV/HAART and the brain — what's going on?

Detalles Bibliográficos
Autor principal:	Portegies, P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112849/ http://dx.doi.org/10.1186/1758-2652-13-S4-O35

Ejemplares similares

Semen may harbor HIV despite effective HAART: another piece in the puzzle
por: Halfon, Philippe, et al.
Publicado: (2010)

Measurements of total and integrated HIV DNA demonstrate sporadic blips of unintegrated HIV DNA in HIV-positive patients on HAART
por: Mexas, A, et al.
Publicado: (2010)

Evolution of tuberculosis/HIV co-infection in California during the HAART Era, 1996-2007
por: Metcalfe, John, et al.
Publicado: (2010)

Overview of osteoimmunology: What's happened? And what's going on?
por: Takayanagi, Hiroshi
Publicado: (2012)

Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART
por: Rusconi, S, et al.
Publicado: (2010)

History of HAART – the true story of how effective multi-drug therapy was developed for treatment of HIV disease
por: Delaney, Martin
Publicado: (2006)

A first-in-man, double blind, placebo controlled study of the candidate therapeutic vaccine Opal-HIV-Gag(c) in HIV infected patients receiving HAART
por: Jackson, AG, et al.
Publicado: (2012)

Risk of death among Italian AIDS cases with AIDS-defining cancers in the post-HAART era
por: Serraino, D, et al.
Publicado: (2009)

A phase 1/PK study of Sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors: AIDS malignancy consortium study 061
por: Deeken, John F, et al.
Publicado: (2012)

Tissue viral dynamics in SIV infected macaques with highly active antiretroviral therapy (HAART)
por: Bourry, Olivier, et al.
Publicado: (2009)

HIV, cyclophilins and nuclear entry: going under the radar
por: Towers, Greg
Publicado: (2011)

The EuResist expert model for customised HAART optimisation: 2010 update and extension to newest compounds
por: Pironti, A, et al.
Publicado: (2010)

Immune-based therapy using gamma interferon ingaron in the treatment of HIV/AIDS patients with active pulmonary tuberculosis (PTB) not previously highly active antiretroviral therapy (HAART)
por: Yola, Auwal, et al.
Publicado: (2006)

Neutralizing anti-Tat antibodies prolonged HAART interruption in vaccines in a prospective structured interruption study
por: Clumeck, Nathan, et al.
Publicado: (2006)

Tenofovir (TDF) containing first-line HAART is associated with changes in plasma parameters suggestive of increased bone resorption
por: Labarga, Pablo, et al.
Publicado: (2010)

Oral lesions among HIV seropositive individuals in an era of generic HAART: markers of HAART efficacy?
por: Vasudevan, Janani, et al.
Publicado: (2012)

Early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) significantly enhance survival of severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis: results of the CAMELIA clinical trial
por: Blanc, François-Xavier, et al.
Publicado: (2011)

What affects the bone in our HIV-positive patients?
por: Fux, CA
Publicado: (2010)

The changing face of HIV resistance; HIV drug resistance north and south — what's next?
por: Schapiro, J
Publicado: (2010)

Go with the flow and accessorize your drugs
por: Schneider, Gisbert
Publicado: (2014)

Trends in human papillomavirus (HPV) infection among HIV-positive women in the pre-HAART and HAART era in a Nigerian clinic
por: Onigbogi, MO, et al.
Publicado: (2010)

Mesenteric fat thickness in a group of HIV patients on HAART
por: Lee, SS, et al.
Publicado: (2010)

HIV-1 infection in dendritic cells in HAART suppressed patients
por: Maldonado, lrvin M, et al.
Publicado: (2006)

Characteristic of HIV/AIDS infected patients at the detection and HAART initiation
por: Holban, Tiberiu, et al.
Publicado: (2014)

Patient safety: why do things go wrong?
por: Flin, R
Publicado: (2004)

Going for the jugular: Has assessment of the JVP become neglected?
por: Artman, B, et al.
Publicado: (2012)

The context of biotechnology - The biotechnologuy sector in Brazil. Going up?
por: Emrich, Eduardo
Publicado: (2014)

Road safety practices among school-going children in Chennai
por: Padankatti, Swathi, et al.
Publicado: (2014)

Prioritisation of specialist health care services: going beyond the evidence
por: Webb, Philip, et al.
Publicado: (2014)

Chemical ontologies: what are they, what are they for and what are the challenges
por: Hastings, Janna, et al.
Publicado: (2011)

"Ready, set, go" - are we facilitating change in the (pre-) contemplative clinician?
por: O'Sullivan, Ulrike, et al.
Publicado: (2014)

Invited talk: What can brain imaging add to neuronal and network representations of pain and attention?
por: Davis, Karen D
Publicado: (2007)

The modular cross-synaptic nature of LTP/LTD following on-going neural activity
por: Loebel, Alex, et al.
Publicado: (2011)

HIV low-level persistent viremia under new antiretroviral regimens: what we have learned up to this point?
por: Gheorghiță, Valeriu, et al.
Publicado: (2014)

Anal and cervical cytologic abnormalities among HIV-infected women in the era of HAART
por: Kojic, EM, et al.
Publicado: (2009)

Neurodegeneration in the HAART era
por: Brew, Bruce J
Publicado: (2010)

NO-insensitive sGCbeta1 H105F knockin mice: if NO has no place to go
por: Thoonen, Robrecht, et al.
Publicado: (2009)

Designing and analysing feasibility studies of complex interventions: challenges related to assessing stop/go criteria
por: Collinson, Michelle, et al.
Publicado: (2013)

Things that go bump in the night: searching for therapeutic targets and underlying mechanisms of night-time calf cramps
por: Hawke, Fiona, et al.
Publicado: (2013)

Are we ready? What is missing and what is needed? A regulator’s perspective
por: Bernardini, Claudia, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_se1gpnkbcb7vc8uo611vu7e6ru